ArticlePharmaceutics2019
Monitoring the Fate of Orally Administered PLGA Nanoformulation for Local Delivery of Therapeutic Drugs.
Article in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Self-assembling nanocomposites for smart drug delivery: towards personalized and stimuli-responsive therapeutics.RSC advances · 2026Review
- Nanoparticle-Based Oral Insulin Delivery: Challenges, Advances, and Future Directions.Pharmaceutics · 2025Review
- Dual action tofacitinib-loaded PLGA nanoparticles alleviate colitis in an IBD mouse model.Drug delivery and translational research · 2025Article
- Nanocarriers and macrophage interaction: from a potential hurdle to an alternative therapeutic strategy.Beilstein journal of nanotechnology · 2025Review
- Development, Characterization and In Vitro Gastrointestinal Release of PLGA Nanoparticles Loaded with Full-Spectrum Cannabis Extracts.AAPS PharmSciTech · 2024Article
- Intracellular Trafficking of Size-Tuned Nanoparticles for Drug Delivery.International journal of molecular sciences · 2023Article
- Article
- Size-Dependent Polymeric Nanoparticle Distribution in a Static versus Dynamic Microfluidic Blood Vessel Model: Implications for Nanoparticle-Based Drug Delivery.ACS applied nano materials · 2023Article
- PLGA Particles in Immunotherapy.Pharmaceutics · 2023Review
- PLGA-Based Nanomedicine: History of Advancement and Development in Clinical Applications of Multiple Diseases.Pharmaceutics · 2022Review
- Ionic co-aggregates (ICAs) based oral drug delivery: Solubilization and permeability improvement.Acta pharmaceutica Sinica. B · 2022Article
- Nanocarriers for Drug Delivery: An Overview with Emphasis on Vitamin D and K Transportation.Nanomaterials (Basel, Switzerland) · 2022Review
- Precision and Advanced Nano-Phytopharmaceuticals for Therapeutic Applications.Nanomaterials (Basel, Switzerland) · 2022Review
- The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update.Pharmaceuticals (Basel, Switzerland) · 2021Review
- PLGA Based Drug Carrier and Pharmaceutical Applications: The Most Recent Advances.Pharmaceutics · 2020Article
- Anti-MAdCAM-1-Conjugated Nanocarriers Delivering Quantum Dots Enable Specific Imaging of Inflammatory Bowel Disease.International journal of nanomedicine · 2020Article
- Polyester nanoparticles delivering chemotherapeutics: Learning from the past and looking to the future to enhance their clinical impact in tumor therapy.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 1 country.
Funding
Abstract
One of the goals of the pharmaceutical sciences is the amelioration of targeted drug delivery. In this context, nanocarrier-dependent transportation represents an ideal method for confronting a broad range of human disorders. In this study, we investigated the possibility of improving the selective release of the anti-cancer drug paclitaxel (PTX) in the gastro-intestinal tract by encapsulating it into the biodegradable nanoparticles made by FDA-approved poly(lactic-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.